دورية أكاديمية
Thoracic radiotherapy timing and prognostic factors in elderly patients with limited‐stage small cell lung cancer
| العنوان: | Thoracic radiotherapy timing and prognostic factors in elderly patients with limited‐stage small cell lung cancer |
|---|---|
| المؤلفون: | Huan Zhao, Yue Qi, Lanfang Zhang, Meng Xing, Fujun Yang |
| المصدر: | Precision Radiation Oncology, Vol 8, Iss 1, Pp 14-21 (2024) |
| بيانات النشر: | Wiley, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Medical physics. Medical radiology. Nuclear medicine LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | elderly patients, intensity modulated radiation therapy, limited‐stage small cell lung cancer, prognosis, radiotherapy timing, thoracic radiotherapy, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Abstract Objective This study assessed the outcomes of elderly patients with limited‐stage small cell lung cancer (LS‐SCLC), which may be linked to the timing of thoracic radiotherapy (TRT) following chemotherapy. Methods Elderly patients (n = 78) with LS‐SCLC were divided into three groups depending on the timing of radiotherapy. The patients in the TRT group were stratified into early (TRT after 1–2 cycles of chemotherapy, n = 29), medium‐term (TRT after 3–4 cycles of chemotherapy, n = 33), and late (TRT after 5–6 cycles of chemotherapy, n = 16) TRT groups. The overall survival (OS) and progression‐free survival (PFS) were assessed and compared. Results The medium‐term TRT group demonstrated significantly longer mPFS (20.12 months) and better mOS (35.97 months) than those in the other groups (PFS: P = 0.021;OS: P = 0.035). A pairwise comparison of the three groups revealed that those who received medium‐term TRT exhibited significantly improved PFS than the early (mPFS: 20.12 vs. 10.36 mouths, P = 0.018) and late (mPFS: 20.12 vs. 9.17 months, P = 0.016) TRT. The medium‐term TRT group demonstrated significantly improved OS than the early TRT (mOS: 35.97 vs. 25.22 months, P = 0.007) but not in comparison with the late TRT (mOS: 35.97 vs. 21.63 months, P = 0.100). Conclusion In elderly patients with LS‐SCLC, the addition of TRT after 3–4 cycles of chemotherapy appears to be a viable and potentially beneficial treatment approach. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2398-7324 53400488 |
| Relation: | https://doaj.org/toc/2398-7324 |
| DOI: | 10.1002/pro6.1223 |
| URL الوصول: | https://doaj.org/article/0e88ca92ff53400488f4cd231765a1fe |
| رقم الأكسشن: | edsdoj.0e88ca92ff53400488f4cd231765a1fe |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 23987324 53400488 |
|---|---|
| DOI: | 10.1002/pro6.1223 |